Published in Int J Mol Sci on January 25, 2017
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol (2008) 5.90
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (2010) 4.52
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
TRIM proteins and cancer. Nat Rev Cancer (2011) 2.84
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood (2010) 2.15
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
Arsenic trioxide, a therapeutic agent for APL. Oncogene (2001) 1.72
Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther (2001) 1.71
PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci (2010) 1.35
Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2011) 1.27
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood (2009) 1.24
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol (2013) 1.14
Differential Roles of PML Isoforms. Front Oncol (2013) 1.13
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells. Chem Res Toxicol (2011) 0.99
Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med (2014) 0.92
Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation. J Biol Chem (2012) 0.87
Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget (2013) 0.86
PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation. J Cell Sci (2013) 0.83
Resistance to therapy in acute promyelocytic leukemia. N Engl J Med (2014) 0.83
Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms. PLoS One (2012) 0.82
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. Ann Hematol (2015) 0.81
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation. Oncotarget (2015) 0.78
Inhibition of Setaria cervi protein tyrosine phosphatases by Phenylarsine oxide: A proteomic and biochemical study. Acta Trop (2016) 0.77